Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
Volume 41, Issue -, Pages 261-295Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev.pharmtox.41.1.261
Keywords
thioredoxin-1; thioredoxin-2; thioredoxin reductase
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA048725, R01CA078277, R01CA077204] Funding Source: NIH RePORTER
- NCI NIH HHS [CA78277, CA77204, CA48725] Funding Source: Medline
Ask authors/readers for more resources
The mammalian thioredoxins are a family of small (approximately 12 kDa) redox proteins that undergo NADPH-dependent reduction by thioredoxin reductase and in turn reduce oxidized cysteine groups on proteins. The two main thioredoxins are thioredoxin-1, a cytosolic and nuclear form, and thioredoxin-2, a mitochondrial form. Thioredoxin-1 has been studied more. It performs many biological actions including the supply of reducing equivalents to thioredoxin peroxidases and ribonucleotide reductase, the regulation of transcription factor activity, and the regulation of enzyme activity by heterodimer formation. Thioredoxin-1 stimulates cell growth and is an inhibitor of apoptosis. Thioredoxins may play a role in a variety of human diseases including cancer. An increased level of thioredoxin-1 is found in many human tumors, where it is associated with aggressive tumor growth. Drugs are being developed that inhibit thioredoxin and that have antitumor activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available